Nestle divests peanut-allergy drug on disappointing uptake
(Bloomberg) Nestle sold its peanut-allergy medicine business to Swiss health-care group Stallergenes Greer after the food company gave up hopes that it would become a blockbuster treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.